While the SYGNAL pipeline highlights key regulatory links (e.g., IRF1‐IKZF1) in GBM and generates high‐confidence inference on GBM‐specific drug‐miRNA combinations, it relies heavily on a thorough compendium of experimental evidence which may not be readily available for other diseases or biological processes. This evidence concerns the gene IRF1 and glioblastoma.